Intervention

Histrelin

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting1

Common conditions7

Lead sponsors shown2

Clinical trials

3 shown

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06

ACTIVE_NOT_RECRUITING

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21

ACTIVE_NOT_RECRUITING

Common conditions

Prostate Adenocarcinoma2 Biochemically Recurrent Prostate Carcinoma1 Castration-resistant Prostate Cancer1 Recurrent Castration-Sensitive Prostate Carcinoma1 Recurrent Prostate Cancer1 Stage III Prostate Cancer AJCC v81 Stage IVA Prostate Cancer AJCC v81

Leading sponsors

NRG Oncology2 Mayo Clinic1

Trial status mix

ACTIVE_NOT_RECRUITING2

RECRUITING1

Phase mix

PHASE32

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.